Alpha Cognition (NASDAQ:ACOG – Get Free Report) is projected to release its Q3 2025 results after the market closes on Thursday, November 13th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $3.2070 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.
Alpha Cognition (NASDAQ:ACOG – Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.19). The company had revenue of $1.66 million for the quarter, compared to analyst estimates of $2.32 million.
Alpha Cognition Price Performance
ACOG stock opened at $6.26 on Tuesday. Alpha Cognition has a one year low of $3.75 and a one year high of $11.54. The stock has a market cap of $130.85 million, a PE ratio of -3.91 and a beta of 2.62. The firm has a 50 day simple moving average of $7.48 and a two-hundred day simple moving average of $8.41.
Insiders Place Their Bets
Institutional Investors Weigh In On Alpha Cognition
Hedge funds and other institutional investors have recently modified their holdings of the stock. Cable Car Capital LP grew its position in Alpha Cognition by 68.8% during the 2nd quarter. Cable Car Capital LP now owns 869,002 shares of the company’s stock worth $8,108,000 after acquiring an additional 354,278 shares during the last quarter. Manatuck Hill Partners LLC boosted its stake in shares of Alpha Cognition by 74.6% during the second quarter. Manatuck Hill Partners LLC now owns 117,000 shares of the company’s stock valued at $1,092,000 after purchasing an additional 50,000 shares during the period. Marshall Wace LLP bought a new position in shares of Alpha Cognition in the second quarter worth approximately $600,000. Massar Capital Management LP bought a new position in shares of Alpha Cognition in the second quarter worth approximately $116,000. Finally, Geode Capital Management LLC purchased a new position in shares of Alpha Cognition in the second quarter worth $112,000.
Analysts Set New Price Targets
A number of research firms have recently issued reports on ACOG. Wall Street Zen downgraded shares of Alpha Cognition from a “hold” rating to a “sell” rating in a report on Saturday, October 18th. HC Wainwright lowered their price target on Alpha Cognition from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, October 20th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $18.00.
View Our Latest Stock Analysis on ACOG
Alpha Cognition Company Profile
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Featured Stories
- Five stocks we like better than Alpha Cognition
- Insider Buying Explained: What Investors Need to Know
- Insiders Sold Big at These 3 Stocks—Should You Worry?
- 3 Warren Buffett Stocks to Buy Now
- Shares Down, Price Targets Up: 3 Stocks Upgraded After +10% Drops
- Financial Services Stocks Investing
- Nuclear Stocks Are Melting Down—Should Investors Panic?
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
